Arş. Gör. Dr. Emir ÇELİK

Yayın Ağı

Makaleler 18

1. Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

EROL C., ŞENDUR M. A. N., Bilgetekin I., BAYIR GARBİOĞLU D., HAMDARD J., Akbas S., et al.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.18, sa.9, ss.347-353, 2022 (SCI-Expanded, Scopus)

2. A rare case of cardiac toxicity in a patient with imatinib treatment: Case report

Samanci N. S., Guliyev M., Degerli E., Celik E., Turna Z. H.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.18, sa.3, ss.792-794, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

3. A single center's experience of the extrapulmonary neuroendocrine carcinomas

ÇELİK E., ŞENGÜL SAMANCI N., Derin S., Bedir S., DEĞERLİ E., ORUÇ K., et al.

NORTHERN CLINICS OF ISTANBUL , cilt.9, sa.1, ss.35-40, 2022 (ESCI, Scopus, TRDizin)

4. The Relationship Between Symptom Severity and Caregiver Burden in Cancer Patients Under Palliative Care: A Cross-Sectional Study

ÇELİK E., ASLAN M. Ş., ŞENGÜL SAMANCI N., Karadag M., Saglam T., Celik Y. C., et al.

JOURNAL OF PALLIATIVE CARE , cilt.37, sa.1, ss.48-54, 2022 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma

5. Classical versus non-classical EGFR mutations: Erlotinib response and impact of renal insufficiency

ÇELİK E., ŞENGÜL SAMANCI N., Karadag M., Demirci N. S., Cikman D. I., Derin S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.27, sa.7, ss.1665-1673, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

6. The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID-19 patients with malignancy: A single-center experience

Degerli E., Derin S., Oruc K., Sengul Samanci N., Bedir S., Celik E., et al.

JOURNAL OF MEDICAL VIROLOGY , cilt.93, sa.10, ss.5839-5845, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

7. Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer

Sengul S., Cikman D., Oruc K., Bedir S., Çelik E., Degerli E., et al.

TUMORI J , cilt.107, sa.4, ss.304-310, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

8. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

Bilgin B., Sendur M. A. N., Yucel S., Celik E., Ozyukseler D. T., Ayhan M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.147, sa.7, ss.2145-2152, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

9. Use of volumetric CT scanning to predict tumor staging and survival in pancreatic cancer patients that are to be administered curative resection

ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., TUTAR O., SAMANCI C., VELİDEDEOĞLU M., et al.

JOURNAL OF SURGICAL ONCOLOGY , cilt.123, sa.8, ss.1757-1763, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

10. Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation

Sengul S., Yılmaz U., Bedir S., Ozgur Y., Oruc K., Durak S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.8, ss.2042-2046, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

11. Patients with acromegaly might not be at higher risk for dopamine agonist- induced impulse control disorders than those with prolactinomas

Ozkaya H. M., Sahin S., Korkmaz O. P., Durcan E., Sahin H. R., Celik E., et al.

GROWTH HORMONE & IGF RESEARCH , cilt.55, 2020 (SCI-Expanded, Scopus)

12. Complete response after ceritinib treatment in non-small cell lung cancer in an elderly patient

Sengul Samanci N., Celik E., Akovali B., Sager S., Demirelli F. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.26, sa.8, ss.2031-2033, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

13. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.

ŞENGÜL SAMANCI N., ÇELİK E., BAĞCILAR Ö., EROL B. Ç., Bicki E., ORUÇ K., et al.

Melanoma research , cilt.30, sa.5, ss.477-483, 2020 (SCI-Expanded, Scopus)

14. The most cited articles on cancer immunotherapy: An update study

ÇELİK E., DOKUR M.

JOURNAL OF BUON , cilt.25, sa.2, ss.1178-1192, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

15. Optic Neuritis Related to Atezolizumab Treatment in a Patient With Metastatic Non-Small-Cell Lung Cancer

Samanci N., Ozan T., Celik E., Demirelli F. H.

JCO ONCOLOGY PRACTICE , cilt.16, sa.2, ss.96-99, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Comparison of Attention for Cancer Research on Social Media Versus Academia: An Altmetric Score Analysis

ÇELİK E., DOKUR M., Borku Uysal B., ŞENGÜL SAMANCI N., DEMİRELLİ F. H.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , cilt.30, sa.1, ss.32-42, 2020 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma

17. The top 100 cited articles in lung cancer - a bibliometric analysis

ŞENGÜL SAMANCI N., ÇELİK E.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY , cilt.24, sa.1, ss.17-28, 2020 (ESCI, Scopus) Sürdürülebilir Kalkınma

18. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up

Celik E., Ozkaya H. M., Poyraz B. C., Saglam T., Kadioglu P.

ENDOCRINE , cilt.62, sa.3, ss.692-700, 2018 (SCI-Expanded, Scopus)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 2

1. Immune-related adverse events associated with immune-checkpoint inhibitors: A single center experience

Samanci N., Oruc K., Bedir S., Celik E., Degerli E., Derin S., et al.

Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, İsviçre, 11 - 14 Aralık 2019, cilt.30, (Özet Bildiri)

2. IMPACT OF INITIAL CHEMOTHERAPY RESPONSE AND PRETRANSPLANT DISEASE STATUS BEFORE AUTOLOGOUS TRANSPLANTATION ON SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA

Yalniz F., Elverdi T., Celik E., Berk S., Erdogan I., Salihoglu A., et al.

20th Congress of European-Hematology-Association, Vienna, Avusturya, 11 - 14 Haziran 2015, cilt.100, ss.744, (Özet Bildiri)

Metrikler

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

100

H-İndeks (Scopus)

Atıf (Scholar)

H-İndeks (Scholar)

Proje

BM Sürdürülebilir Kalkınma Amaçları

Yayınlar & Eserler